Drug Approval | January 03, 2022
Emcure to launch oral Covid-19 drug soon
A toll-free helpline to be set up to help doctors and patients
A toll-free helpline to be set up to help doctors and patients
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Filing marks first protein-based vaccine submitted to MHRA for authorization
Subscribe To Our Newsletter & Stay Updated
